Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu,

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at 
Nanomaterials Technology Transfer Conference in Corfu, Greece 
CAMBRIDGE, MA -- (Marketwired) -- 07/16/13 --   Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company
and developer of AC5(TM), a novel product aimed at controlling
bleeding and fluid loss in order to provide faster and safer surgical
and interventional care, is pleased to advise that co-founding and
inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a keynote
lecture titled "Translating Nanomedicine: Molecular medical devices
from Nano Neuro Knitting to Immediate Hemostasis to Cancer Stem Cell
Arrest" in Corfu, Greece at the Technology Transfer Workshop: From
the Lab to the Marketplace.  
Dr. Ellis-Behnke was instrumental in discovering the hemostatic and
other barrier properties of self-assembling peptides that could make
future surgery and interventional care faster and safer through the
development and proposed commercialization of the Company's flagship
product candidate known as AC5(TM). The product is based on a
self-assembling peptide solution that creates a physical, mechanical
barrier, which could be applied to bleeding organs or wounds to seal
leaking blood and other fluids.  
Dr. Ellis-Behnke presented during a day-long special workshop,
addressing nanotechnology transfer, which was part of a larger
four-day conference, the 4th International Conference for
Nanoparticles and Nanomaterials to Nanodevices and Nanosystems, which
reviewed the current state-of-the-art in nanoscience and
nanotechnology, and identifies challenging and rewarding research
directions.  
Ellis-Behnke talked about his discovery of new molecular medical
devices and how they will change medicine and the entire healthcare
system. "Controlling the healing process is critical for the recovery
of any injury, especially burn trauma," Ellis-Behnke continues,
"First a barrier must be created to stop bleeding. In a surgical
setting, we've shown that we can stop bleeding in small and large
animals in less than 15 seconds, in multiple tissues, as well as a
variety of different wounds, using a self-assembling peptide that
creates a barrier and incorporates it into the surrounding tissue to
form an extracellular matrix. This is all achieved without clotting
and we've found that it does not induce an immune response." 
An added benefit of the nanomaterial is that it is optically
transparent. "Placing it on a wound not only stops the bleeding
quickly and creates a barrier; it also provides a clear view of the
surgical field while operating through it." 
"This technology will impact the operating room in a fundamental way
through the reduction in procedure time, along with the ability to
control the environment so operations can be performed in less than
optimal conditions while maintaining surgical field integrity," said
Ellis-Behnke. "The time to perform an operation could potentially be
reduced by up to 50 percent."  
Additional details regarding Arch Therapeutics, Inc., its business,
agreements and related matters are filed as part of the Company's
continuous public disclosure as a reporting issuer under the
Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission ("SEC"), and are available at the SEC's website
at www.sec.gov. For more information, visit our website at
www.archtherapeutics.com. 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
(OTCQB: ARTH) is a medical device company developing a novel approach
to stop bleeding (hemostasis) and control leaking (sealant) during
surgery and trauma care. Arch's goal is to develop and commercialize
products based on our innovative technology platform that make
surgery and interventional care faster and safer for patients. Arch's
flagship development stage product candidate known as AC5(TM) is
being designed to elegantly achieve hemostasis in minimally invasive
and open surgical procedures. Find out more at
www.archtherapeutics.com.  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at
www.sec.gov. 
On Behalf of the Board, 
Terrence W. Norchi, MD.
 Arch Therapeutics, Inc. 
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com 
Website: www.archtherapeutics.com 
 
 
Press spacebar to pause and continue. Press esc to stop.